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A photoactive iodoarylazide derivative (I-APA-PhNJ of the competitive thromboxane AJprostaglandin 
H, (TXA~PGH~ antagonist t3-azaprostanoic acid is evaluated. Upon photoactivation, the compound was 
found to inhibit specifically and irreversibly human platelet aggregation induced by the TXAJPGH, mimet- 
ic U46619. In receptor-binding studies using [3H]U46619, I-APA-PhN, exhibited an IC,, of 300 nM for 
inhibition of U46619 binding. Photoactivation of I-APA-PhN, resulted in an irreversible 58% reduction in 
specific binding of U46619. This compound and its corresponding radio-iodinated form will prove to be 
useful tools for the isolation and purification of the TXAJPGH,-binding protein in human platelets. 
Platelet; Thromboxane receptor; Photoa~nity label; U46619 
1. INTRODUCTION 
Through their actions as potent vasoconstrictors 
and platelet-aggregating agents, thromboxane AZ 
(TXAz) and prostaglandin HZ (PGHz) are likely 
contributors to the pathogenesis of thrombosis, 
atherosclerosis and angina. This has resulted in 
considerable interest in the nature of the 
TXA2/PG& receptor. +A number of specific an- 
tagonists [I-S] and radioligands [6-lo] have been 
employed to study the TXAz/PGHz-binding site, 
and one of the major goals of research in this area 
is the complete purification and characterization 
of this protein. 
In this connection, the development of photoaf- 
finity labelling techniques using radioactive probes 
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has aided greatly in the identification and purifica- 
tion of hormone and drug receptors [ 11,121. Thus, 
we have synthesized 17,18,19,20-tetranor-16-(3’- 
iodo4’-azidophenyl)-13azaprostanoic acid (I- 
APA-PhN3, fig.l), a derivative of the competitive 
TXA2/PGH2 antagonist trans-l3-azaprostanoic 
acid (13-APA). I-APA-PhN:, incorporates a 
photoactive iodophenyl~de moiety and is easily 
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Fig.1. Structures of 13-APA (l), I-APA-PhN3 (2) and 
APA-0-PhNa (3). 
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biological characterization of this new photoaffini- 
ty label for the TXAz/PGHz receptor. 
2. MATERIALS AND METHODS 
2.1. Aggregation studies 
The synthesis of I-APA-PhN3 has been de- 
scribed [ 13,141. Platelet-rich plasma (PRP) was 
prepared from blood collected into 0.38% citrate- 
phosphate-dextrose-adenine from healthy, drug- 
free donors. All aggregations were performed by 
the turbidometric method [16], and contained 
20pM indomethacin. Drugs or vehicle (95% 
ethanol) were added 1 min prior to the aggregating 
agent. In photoactivation studies, PRP containing 
20 pM I-APA-PhNs was subjected to 30 min of 
UV irradiation from a 100 W mercury lamp. The 
platelets were sedimented by centrifugation, 
resuspended in buffer A (145 mM NaCl, 5 mM 
KCI, 1 mM MgS04, 0.5 mM Na2HP04, 5 mM 
glucose, 10 mM Hepes, pH 7.4), and aggregated as 
described above. 
2.2. Receptor studies 
[‘H]U46619 (22.4 Ci/mmol, gift of Dr E. Do, 
New England Nuclear, Boston, MA) was 
employed as a radiolabelled TXAzlPGHz mimetic 
P9171. 
2.2.1. Binding inhibition studies 
Platelets were treated with 1 mM aspirin, 
removed from plasma and resuspended in buffer I3 
(138 mM NaCl, 5 mM KCl, 5 mM MgCl2,5.5 mM 
glucose, 25 mM Tris-HCI, pH 7.4) to a cell count 
of 3-5 x lO*/ml. For the binding inhibition study, 
platelets were incubated in darkness for 5 min with 
I nM [3H]U46619 in the presence of vehicle (total 
binding) or with increasing concentrations of I- 
APA-PhN3. Nonspecific binding was assessed in a 
separate incubation in the presence of 1 PM 
unlabelled U46619. Specific binding is defined as 
the difference between total and nonspecific 
binding, and was 70-75% of total binding. Ali- 
quots (1 ml) of the binding incubation mixture 
were filtered rapidly under vacuum through What- 
man GF/C filters and washed 3 times with 5 ml 
ice-cold buffer B. [3H]U46619 activity on the 
filters was determined in a Beckman LS6800 liquid 
scintillation spectrometer. 
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2.2.2. Photoactivation studies 
Cells were incubated in darkness for 5 min with 
20pM I-APA-PhN3 or vehicle, after which 
samples were divided into two equal portions. One 
portion from the I-APA-PhN3 and control groups 
was subjected to photolysis for 2 min, while the 
other was incubated in darkness for an additional 
2 min. Cells were then washed and resuspended 
three times in buffer B containing 3.8% (w/w) 
bovine serum albumin (Sigma, St. Louis, MO) to 
remove free I-APA-PhN3, and resuspended in buf- 
fer B at a concentration of 3-5 x lO*/ml. The 
binding assay was conducted as described for the 
inhibition studies. 
3. RESULTS 
Aggregation induced by 3 yM U46619 (the 
minimum dose necessary to produce maximal ag- 
gregation in PRP) was completely inhibited by 
IOpM I-APA-PhN3, as shown in fig.2C. In con- 
trast, 25 PM 13-APA was required to achieve the 
same degree of inhibition at the same agonist dose 
(fig.2B). Furthermore, it was found that I-APA- 
TIME (An) IME (min) TIME (min) 
Fig.2. Effects of 13-APA and I-APA-PhN3 on pIatelet 
aggregation. PRP was incubated with 20/1M 
indomethacin (ah traces) and ethanol vehicle (A,D), 
25 ,uM 13-APA (B,E) or 10 pM I-APA-PhNs (C,F) for 
1 min prior to agonist addition. Agonist doses were 
3 FM U46619 (A-C), 4pM A23187 and 5 ,uM ADP 
(D-F, as shown). 
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PhN, like 13-APA, was pharmacologically 
specific since it had no effect on either ADP or 
A23187 induced aggregation (fig.2E,F). Fig.3 
shows that after incubation with I-APA-PhN3 
under photoactivating conditions and removal of 
free drug, U46619 aggregation remained greater 
than 90% inhibited (fig.3C). On the other hand, 
resuspension completely reversed inhibition of 
U46619 aggregation by the competitive antagonist, 
13-APA (fig.3B). As before, A23187- and ADP- 
induced aggregation was unaffected by either I- 
APA-PhN3 or 13-APA (fig.3E,F). 
To demonstrate further that the phar- 
macological effects of I-APA-PhN3 on platelet ag- 
gregation resulted from action at the TXAz/PGH2 
receptor, binding studies using [3H]U46619 were 
performed. I-APA-PhN3 was found to inhibit the 
specific binding of [3H]U46619 in a dose- 
dependent manner, with the concentration for 
50% inhibition being approx. 300 nM (fig.4). 
Irreversible inhibition of U46619 binding by 
photoactivation of I-APA-PhN3 is illustrated in 
fig.5. Platelets were irradiated or dark incubated 
TIME (min) TIME (min) TIME (min) 
Fig.3. Irreversibility of aggregation inhibition after 
photolysis. PRP was incubated with vehicle (A,C), 
50 pM 13-APA (B,E) or 20 PM I-APA-PhN3 (C,F) for 
30 min in the presence of UV light. Platelets were 
sedimented by centrifugation and resuspended in buffer 
A. Following addition of 20 PM indomethacin, platelets 
were aggregated to 0.2 FM U46619 (A-C), 2 pM A23187 
and 5 pM ADP (D-F, as shown). 
LOG [I-APA-Pht+] nM 
Fig.4. Inhibition of specific binding of [3H]U46619 by I- 
APA-PhN3 in aspirin-treated human platelets resus- 
in buffer B. Each point is the average of 2 
experiments performed in duplicate. 
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Fig.5. Photoactivation and irreversible inhibition of 
[3H)U46619 binding by I-APA-PhNs. Aspirin-treated 
platelets resuspended in buffer B were incubated 5 min 
in darkness with 20,uM I-APA-PhN3 or its vehicle 
(controls). Samples were divided and either photolysed 
for 2 min [control (L) and I-APA-PhN3 (L)] or left in 
darkness an additional 2 min [control (D) and I-APA- 
PhN3 (D)], followed by washing 3 times with buffer B 
containing 3.8% (w/w) bovine serum albumin. After 
resuspension in buffer B (without albumin) at 3-5 x 10’ 
platelets/ml, i3H]U46619 binding was assessed. Values 
above bars are specifically bound dpm/lO* platelets 
(mean + SE, n = 7). 
with 20pM I-APA-PhN3 or its vehicle (control), 
washed three times to remove drug and resuspend- 
ed. It was found that exposure to UV light alone 
had no effect on the binding of t3H]U46619. 
However, photolysis in the presence of I-APA- 
PhN3 [I-APA-PhN3 (L) in fig.51 resulted in an ir- 
reversible 58% inhibition of specific U46619 
181 
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binding compared to control cells. In the absence 
of photolysis, incubation of cells with I-APA- 
PhN3 [I-APA-PhN3 (D) in fig.51 resulted in a 
smaller loss (32%) of U46619 specific binding. 
This small amount of receptor apparently inac- 
tivated in the absence of photolysis may be due to 
inadequate removal of the drug by the washing 
procedure or a dark reaction in which the com- 
pound is nonphotochemically incorporated into 
the receptor. 
4. DISCUSSION 
In recent years the use of radioactive photoaf- 
finity labelling techniques has been of significant 
value in the isolation, purification and 
characterization of receptor proteins from a varie- 
ty of cells. Thus, the incorporation of a radiolabel 
into a photolabile molecule provides a unique 
means of marking receptors throughout the 
various stages of protein purification. To this end, 
we have synthesized two potential photoaffinity 
probes for the TXAz/PGHz receptor: I-APA- 
PhN3 and a phenoxyarylazide 13-APA derivative 
(APA-0-PhN3, fig.1) 113,141. 
In APA-0-PhN3 the photoactive arylazide 
group is attached to the molecule via an ether 
linkage. Presumably, because of the lability of this 
phenoxide bond, the molecule could not be 
iodinated. In addition, photoactivation of the 
molecule resulted in irreversible but non-specific 
inhibition of human platelet aggregation (not 
shown). Based on these characteristics APA-O- 
PhN3 was not considered to be a useful photoaf- 
finity label for the receptor. Subsequent o syn- 
thesis of our compounds, another phenoxy-linked 
molecule has also been reported as a photoaffinity 
probe for the TXA2/PGH2 receptor [ 181. 
However, this aryldiazonium salt, like our 
phenoxy compound, was not iodinated. 
In contrast to APA-0-PhN3, the methylene 
series was readily iodinated to give I-APA-PhN3 
and the corresponding radiolabelled derivative, 
‘251-APA-PhNs, having a specific activity of 
600 Ci/mmol (13,141. These compounds, one of 
which is radiolabelled, are the first reported 
photoaffinity probes for the TXA21PGH2 recep- 
tor. Fu~hermore, the results reported here 
demonstrate the following: (i) an iodophenylazide 
group can be incorporated into the structure of 
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13-APA without loss of biological potency and 
specificity; (ii) I-APA-PhN3 can irreversibly inhibit 
platelet aggregation induced by U46619; (iii) I- 
APA-PhN3 can irreversibly inhibit binding of 
[3H]U46619 to its binding site, presumably the 
TXA2/PGH2 receptor; and (iv) photoactivation of 
the molecule results in a significant increase in the 
irreversible receptor blockade. Taken together, 
these data indicate that I-APA-PhNs and its cor- 
responding radio-iodinated derivative will be 
valuable tools for molecular characterization, 
isolation and purification of the putative 
TXAzfPGH2 receptor. 
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